23rd Jan 2019 11:20
LONDON (Alliance News) - Renalytix AI PLC on Wednesday said it has started a clinical validation study of KidneyIntelX for diagnosing fast-progressing kidney disease.
KidneyIntelX is designed to diagnose and improve clinical management of patients with Type II diabetes and those with fast-progressing kidney disease. The study will assess 5,000 patient blood samples.
The company said: "Identification of patients with chronic kidney disease who are at risk of, or are experiencing, rapid kidney function decline is challenging.
"However, the KidneyIntelX test will significantly improve the identification of these patients in the early stages, thereby improving care and outcomes for these patients through early initiation or escalation of treatment strategies."
RenalytixAI expects to commercially launch KidneyIntelX as a laboratory developed test in its laboratory facilities to health systems and drug developers during the second half of 2019.
"The scale and clinical breadth of this validation provides a rare opportunity to evaluate how AI can aid our ability to detect fast-progressing kidney disease. KidneyIntelX will give doctors a powerful tool to identify which individuals with kidney disease are likely to progress to end-stage disease and should be treated more aggressively," Chief Medical Officer Michael Donovan said.
Renalytix shares were untraded on Wednesday, last quoted at 125.00 pence each.
Related Shares:
Renalytix Plc